Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks: A Phase II Randomized Controlled Trial (OraGO-1 Trial)

NCT06392906 is registered in ClinicalTrials.gov with Janjira Petsuksiri as lead sponsor.

NCT NCT06392906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06392906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks: A Phase II Randomized Controlled Trial (OraGO-1 Trial)
Lead sponsor
Janjira Petsuksiri
Phase
Phase 3
Overall status
Recruiting
Start date
July 11, 2024
Completion date
October 31, 2028
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid associated ophthalmopathy